Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2009 08:00 ET | Source: Myrexis, Inc.

Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma

SALT LAKE CITY, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa(TM)...
November 16, 2009 08:00 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies

SALT LAKE CITY, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preliminary phase 1 data for MPC-3100, its fully-synthetic small...
November 12, 2009 17:21 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results

SALT LAKE CITY, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its first fiscal quarter ended September 30, 2009. "We are pleased...
October 23, 2009 14:30 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)

SALT LAKE CITY, Oct. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of...
October 20, 2009 08:00 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Announces Presentation on Azixa(TM) at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors

SALT LAKE CITY, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that an abstract has been selected for oral presentation at the 2009 Joint Meeting of the...
October 13, 2009 16:20 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Announces the Identification of an IND Candidate for the Treatment of Cancer, Obesity, and Diabetes

SALT LAKE CITY, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the identification of an Investigational New Drug (IND) candidate targeting a novel...
September 15, 2009 08:00 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Elects Timothy R. Franson, M.D. to Its Board of Directors

SALT LAKE CITY, Sept. 15, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) announced today that it has elected Timothy R. Franson, M.D. to its Board of Directors. Dr. Franson's term...
September 14, 2009 14:42 ET | Source: Myrexis, Inc.

Myriad Pharmaceutical's Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients

SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel...
September 10, 2009 18:00 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals Announces Two Abstracts Selected for Presentation At 2009 ICAAC Annual Meeting

SALT LAKE CITY, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that two abstracts have been selected for presentation at the Interscience Conference on...
September 03, 2009 18:00 ET | Source: Myrexis, Inc.

Myriad Pharmaceuticals, Inc. to Present At Upcoming Investor Conferences

SALT LAKE CITY, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right